Participants who met any of the following criteria were excluded from the study: recent use of or intolerable side effects related to an SGLT2 inhibitor, presence of type 1 diabetes mellitus, hypotension symptoms or a systolic blood pressure below 90 mm Hg, and an estimated glomerular filtration rate (eGFR) lower than 30 ml per minute per 1.73 m2 of body surface area (or experiencing rapid decline in renal function). Here, SLC5A2 is linked to diabetes mellitus.